- Home
- About Us
- Our Products
- Investors
- News
- New Product Pipeline
- Contact Us
Pharmaxis Ltd requests an immediate trading halt of its securities pending the announcement of results from its second international Phase III trial of Bronchitol® in patients with cystic fibrosis.